Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Immune Drug for Deadly Skin Cancer Shows Long-Term Survival

May 19, 2016 9:07 am | by Lindsay Tanner, AP Medical Writer | News | Comments

A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. 

TOPICS:

BMS Announces Positive Phase 3 Study Results for Opdivo

May 19, 2016 8:33 am | News | Comments

Findings to be presented at the meeting will also include additional research to explore biomarkers that may help predict outcomes with Opdivo.

TOPICS:

Roche Wins FDA Approval for Bladder Cancer Immunotherapy

May 19, 2016 8:21 am | by Ryan Bushey, Digital Editor | Articles | Comments

The drug is expected to bring around $2.5 billion in annual sales by 2020. 

TOPICS:
Advertisement

Large HIV Vaccine Study Planned in South Africa

May 19, 2016 8:00 am | by The Associated Press | News | Comments

Scientists are planning a major study of an experimental HIV vaccine in South Africa later this year.

TOPICS:

Antidote to Opioid Drug Overdoses Could Become More Accessible

May 19, 2016 7:30 am | by American Chemical Society | News | Comments

Over the past 15 years, deaths caused by heroin and prescription opioid overdoses have quadrupled despite the existence of a highly effective antidote.

TOPICS:

Collaborating to Explore Cancer Therapy Resistance

May 18, 2016 2:00 pm | by Northwestern University | News | Comments

The strategy has potential for use in treating other cancers.

TOPICS:

High Levels of Protein p62 Predict Liver Cancer Recurrence

May 18, 2016 11:49 am | News | Comments

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. 

TOPICS:

AstraZeneca’s Lynparza Fails in Gastric Cancer Phase 3 Trial

May 18, 2016 9:35 am | by Stephanie Guzowski, Editor | News | Comments

AstraZeneca announced Wednesday that its recently approved ovarian cancer treatment Lynparza (olaparib) missed a primary endpoint of improving overall survival in patients with advanced gastric cancer.

TOPICS:
Advertisement

Cellular Immunotherapies Represent Long-Term Opportunity in Immuno-Oncology Space

May 18, 2016 9:00 am | by Dan Roberts, Ph.D., Senior Oncology & Hematology Analyst, GlobalData | Articles | Comments

Early studies of these drugs have demonstrated very impressive remission rates of up to 90 percent.

TOPICS:

Valeant Announces Expanded Discounts for Nitropress, Isuprel

May 18, 2016 8:59 am | News | Comments

The company will make available to all hospitals in the U.S. an enhanced rebate program to reduce the price of both heart drugs.

TOPICS:

Colombia Battles World's Biggest Drugmaker Over Cancer Drug

May 18, 2016 8:39 am | by Joshua Goodman and Linda A. Johnson, Associated Press | News | Comments

Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.

TOPICS:

FT Summit Hosts Heated Debate on Drug Pricing

May 18, 2016 8:22 am | by Ryan Bushey, Digital Editor | Articles | Comments

All participants presented intriguing viewpoints for this controversial topic. 

TOPICS:

Biogen, UPenn to Collaborate on Multiple Gene Therapy Programs

May 18, 2016 8:10 am | News | Comments

The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system (CNS)

TOPICS:

Novartis Separates Drug Business into Pharmaceuticals, Oncology Divisions

May 18, 2016 8:00 am | News | Comments

The new structure reflects the importance of oncology to Novartis following the successful integration of the oncology assets acquired from GSK.

TOPICS:

Study Advances Understanding of Colon Cancer and Colitis

May 18, 2016 7:45 am | by University of California Riverside | News | Comments

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the main types, is on the increase in the United States. 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading